Raising the standards of patient‐centered outcomes research in myelodysplastic syndromes : Clinical utility and validation of the subscales of the QUALMS from the MDS‐RIGHT project
Abstract Background Clinical decision‐making for patients with myelodysplastic syndromes (MDS) is challenging, and both disease and treatment effects heavily impact health‐related quality of life (HRQoL) of these patients. Therefore, disease‐specific HRQoL measures can be critical to harness the patient voice in MDS research. Methods We report a prospective international validation study of the Quality of Life in Myelodysplasia Scale (QUALMS) with a main focus on providing information on the psychometric characteristics of its three subscales: physical burden (QUALMS‐P), emotional burden (QUALMS‐E), and benefit finding (QUALMS‐BF). The analysis is based on patients enrolled from three European countries and Israel, participating to the MDS‐RIGHT Project. The scale structure and psychometric properties of the QUALMS were assessed. Results Overall, 270 patients with a median age of 74 years were analyzed and the majority of them (60.3%) had a low MDS‐Comorbidity Index score. Results of the confirmatory factor analysis supported the underlying scale structure of the QUALMS, which, in addition to a total score, includes three subscales: QUALMS‐P, QUALMS‐E, and the QUALMS‐BF. The QUALMS‐P exhibited the highest Cronbach's alpha coefficients. Discriminant validity analysis indicated good results with the QUALMS‐P and QUALMS‐E distinguishing between patients with different performance status, comorbidity, anemia, and transfusion dependency status. No floor and ceiling effects were observed. Responsiveness to change analysis supported the validity of the measure. Patients with a hemoglobin (Hb) level of <11 g/dL at study entry, who subsequently showed an improvement in their Hb levels, also reported a mean score change of 9 and 8 points (scales ranging between 0 and 100) in the expected direction of the QUALMS‐E and QUALMS‐P, respectively. Conclusions Our study provides additional validation data on the QUALMS from the international MDS‐RIGHT Project. The use of this disease‐specific HRQoL measure may contribute to raise quality standards of patient‐centered outcomes research in MDS..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer Medicine - 12(2023), 6, Seite 7529-7539 |
| Beteiligte Personen: |
Efficace, Fabio [VerfasserIn] |
|---|
| Anmerkungen: |
© 2023 Published by John Wiley & Sons Ltd. |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1002/cam4.5487 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY015230910 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY015230910 | ||
| 003 | DE-627 | ||
| 005 | 20231111134009.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231111s2023 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/cam4.5487 |2 doi | |
| 028 | 5 | 2 | |a 2023-11-11_CAM4_2023_12_6.zip.xml |
| 035 | |a (DE-627)WLY015230910 | ||
| 035 | |a (WILEY)CAM45487 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 100 | 1 | |a Efficace, Fabio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Raising the standards of patient‐centered outcomes research in myelodysplastic syndromes |b Clinical utility and validation of the subscales of the QUALMS from the MDS‐RIGHT project |
| 264 | 1 | |c 2023 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Published by John Wiley & Sons Ltd. | ||
| 520 | |a Abstract Background Clinical decision‐making for patients with myelodysplastic syndromes (MDS) is challenging, and both disease and treatment effects heavily impact health‐related quality of life (HRQoL) of these patients. Therefore, disease‐specific HRQoL measures can be critical to harness the patient voice in MDS research. Methods We report a prospective international validation study of the Quality of Life in Myelodysplasia Scale (QUALMS) with a main focus on providing information on the psychometric characteristics of its three subscales: physical burden (QUALMS‐P), emotional burden (QUALMS‐E), and benefit finding (QUALMS‐BF). The analysis is based on patients enrolled from three European countries and Israel, participating to the MDS‐RIGHT Project. The scale structure and psychometric properties of the QUALMS were assessed. Results Overall, 270 patients with a median age of 74 years were analyzed and the majority of them (60.3%) had a low MDS‐Comorbidity Index score. Results of the confirmatory factor analysis supported the underlying scale structure of the QUALMS, which, in addition to a total score, includes three subscales: QUALMS‐P, QUALMS‐E, and the QUALMS‐BF. The QUALMS‐P exhibited the highest Cronbach's alpha coefficients. Discriminant validity analysis indicated good results with the QUALMS‐P and QUALMS‐E distinguishing between patients with different performance status, comorbidity, anemia, and transfusion dependency status. No floor and ceiling effects were observed. Responsiveness to change analysis supported the validity of the measure. Patients with a hemoglobin (Hb) level of <11 g/dL at study entry, who subsequently showed an improvement in their Hb levels, also reported a mean score change of 9 and 8 points (scales ranging between 0 and 100) in the expected direction of the QUALMS‐E and QUALMS‐P, respectively. Conclusions Our study provides additional validation data on the QUALMS from the international MDS‐RIGHT Project. The use of this disease‐specific HRQoL measure may contribute to raise quality standards of patient‐centered outcomes research in MDS. | ||
| 700 | 1 | |a Koinig, Karin |4 aut | |
| 700 | 1 | |a Cottone, Francesco |4 aut | |
| 700 | 1 | |a Bowen, David |4 aut | |
| 700 | 1 | |a Mittelman, Moshe |4 aut | |
| 700 | 1 | |a Sommer, Kathrin |4 aut | |
| 700 | 1 | |a Langemeijer, Saskia |4 aut | |
| 700 | 1 | |a Culligan, Dominic |4 aut | |
| 700 | 1 | |a Filanovsky, Kalman |4 aut | |
| 700 | 1 | |a Storck, Michael |4 aut | |
| 700 | 1 | |a Smith, Alexandra |4 aut | |
| 700 | 1 | |a van Marrewijk, Corine |4 aut | |
| 700 | 1 | |a Dugas, Martin |4 aut | |
| 700 | 1 | |a Stojkov, Igor |4 aut | |
| 700 | 1 | |a Siebert, Uwe |4 aut | |
| 700 | 1 | |a de Witte, Theo |4 aut | |
| 700 | 1 | |a Stauder, Reinhard |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer Medicine |g 12(2023), 6, Seite 7529-7539 |w (DE-627)WLY003024768 |x 20457634 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:6 |g pages:7529-7539 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 6 |h 7529-7539 |g 11 | ||